Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Novartis has agreed to pay Voyager Therapeutics up to $1.3 billion for access to novel AAV capsids the biotech has developed through its TRACER platform. The…
Voyager Therapeutics has landed its second Big Pharma capsid-licensing pact in a month, agreeing to provide Novartis with access to its TRACER AAV capsids for…
Voyager Therapeutics entered a strategic collaboration and capsid license agreement with Novartis Pharma AG to advance gene therapies for Huntington's disease…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
Voyager Therapeutics entered a capsid license agreement and strategic collaboration with Novartis (announced January 2, 2024) to advance AAV gene therapies for Huntington's disease (HD) and spinal muscular atrophy (SMA) using Voyager's TRACER capsid platform. Voyager received $100M upfront ($80M cash plus a $20M equity investment in newly issued shares) and is eligible for up to $1.2B in preclinical, development, regulatory and sales milestones, plus tiered royalties on TRACER-enabled products (total potential value ~$1.3B). Novartis takes worldwide rights to the HD gene therapy (Voyager leads preclinical; Novartis leads clinical development and commercialization) and target-exclusive TRACER access for the SMA program, which Novartis develops and commercializes.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Voyager Therapeutics Inc. (this deal) | 2023 | $1.3B | — |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2023 deals · Novartis AG deals · Neurology deals